Brief: Zynerba Pharmaceuticals Presents Positive Data From Phase 2 Inspire Trial
14/09/2023 22:03
Sept 14 (Reuters) - Zynerba Pharmaceuticals Inc
ZYNE.O :
* ZYNERBA PHARMACEUTICALS PRESENTS POSITIVE DATA FROM PHASE
2
INSPIRE TRIAL IN 22Q11.2 DELETION SYNDROME AT THE SOCIETY FOR
THE STUDY OF BEHAVIOURAL PHENOTYPES (SSBP) 25TH INTERNATIONAL
RESEARCH SYMPOSIUM
Source text for Eikon: ID:nGNX3HDpvb
Further company coverage: ZYNE.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Zynerba Pharmaceuticals
See all newsBrief: Harmony Biosciences Completes Acquisition Of Zynerba Pharmaceuticals
Brief: Harmony Biosciences Announces Extension Of Tender Offer To Acquire Zynerba Pharmaceuticals, Inc.
Brief: Zynerba Pharmaceuticals Presents Positive Data From Phase 2 Inspire Trial
U.S. RESEARCH ROUNDUP-Easterly Government Properties, Visa, Zynerba Pharmaceuticals
Zynerba Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary